ANG Lifesciences India Limited has announced that its board meeting is scheduled to be held on May 30, 2026. The meeting will take place at the registered office of the company located at Darbara Complex, SCO-113, District Shopping Centre, B Block, Ranjit Avenue, Amritsar-143001, at 05:00 P.M.

The primary agenda for the meeting is to consider and approve the standalone and consolidated audited financial results of the company for the quarter and year ended March 31, 2026. The board will also discuss any other business that may be necessary with the permission of the Chairman.

In compliance with the SEBI (Prohibition of Insider Trading) Regulations and the company's code of conduct, the trading window has been closed since April 1, 2026. This closure is intended to prevent insider trading and ensure the fair disclosure of unpublished price-sensitive information. The window will remain closed until 48 hours after the financial results are made public on May 30, 2026.

The intimation was addressed to the Department of Corporate Services at BSE Limited. The company's BSE security code is 540694. The communication was signed by Rajesh Gupta, Managing Director, on behalf of ang lifesciences .

Key Meeting Details

ANG Lifesciences India Limited has disclosed to BSE that it does not qualify as a Large Corporate for the financial year 2025-26, making SEBI's borrowing requirements non-applicable to the company. The disclosure was made through a formal communication dated April 17, 2026, signed by Managing Director Rajesh Gupta.

Regulatory Compliance Status

The company's disclosure references several key regulatory circulars that govern Large Corporate borrowing requirements:

These circulars specifically address fund raising through issuance of debt securities by Large Corporates and the associated disclosure compliance requirements.

Annual Disclosure Exemption

Since ANG Lifesciences does not fall under the Large Corporate category for FY26, the company is exempt from filing the Annual Disclosure mentioned in Annexure B1 of the relevant SEBI circular. This exemption applies specifically to the financial year 2025-26 disclosure requirements.

Future Compliance Commitment

The company has provided assurance regarding future compliance obligations. Management stated that if ANG Lifesciences meets the Large Corporate criteria in future periods, it will:

• Inform BSE of the change in status
• Fulfill all applicable requirements for Large Corporates
• Ensure complete compliance with relevant regulations

Company Details

The disclosure was submitted under the company's CIN number L24230PB2006PLC030341 and GST number 02AAHCA5390H2ZT. The communication was addressed to the Department of Corporate Services at BSE Limited, referencing the company's script code 540694.

This regulatory disclosure ensures transparency regarding the company's compliance status and demonstrates proactive communication with market regulators regarding applicable borrowing requirements.